Pfizer Secures Early Patient Access In UK For Eczema Drug Abrocitinib
Company Expects To File For Approval Within Next Few Months
Executive Summary
The UK is allowing certain patients with severe atopic dermatitis to be treated with Pfizer’s yet-to-be-approved abrocitinib, which is under review in several countries.